Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the first clinical readout from ...

Guardant Health, Inc., a leading precision oncology company, announced the availability of Guardant Reveal™, the first blood-only liquid biopsy test for the detection of residual and recurrent ...

LIBERATE Study: Guardant Reveal showed high sensitivity and 100% positive predictive value for relapse The LIBERATE study retrospectively analyzed 290 blood samples from 95 patients who were ...

Guardant Reveal test sensitivity and specificity were 55.6% and 100% respectively for this single timepoint. By incorporating longitudinal surveillance samples, sensitivity improved to 91%.

Guardant Health has commercially launched liquid biopsy-based Guardant360 ®, Guardant360 CDx, and GuardantOMNI ® tests for advanced stage cancer patients, and Guardant Reveal ™ test for early ...

Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers 1,000-patient prospective study in 11 solid tumors ...

Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal ...

Dive Insight: Guardant launched its Reveal blood test in February 2021. The product detects residual and recurrent colorectal cancer to identify people who may benefit from post-surgery chemotherapy.

Eltoukhy said Guardant Reveal would stand out within what his company has projected is a $15-billion addressable market consisting of the nation’s 15 million early-stage cancer survivors, based ...

Guardant Health, Inc. (NASDAQ:GH) Q1 2025 Earnings Call Transcript April 30, 2025 Guardant Health, Inc. beats earnings expectations. Reported EPS is $-0.49, expectations were $-0.61. Operator ...

Guardant Reveal uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA) in a patient’s blood without the need for a tissue sample.